BlueRock Therapeutics Resources Archive

Poster

Presented at MDS

2024

Motor and Non-Motor Outcomes of Bemdaneprocel in People With Parkinson’s Disease: Results up to 24 Months From a Phase 1 Study

Claire Henchcliffe, MD, DPhil; Harini Sarva, MD; Andres Lozano, MD, PhD; Alfonso Fasano, MD, PhD; Suneil Kalia, MD, PhD, FAANS, FRCSC; Kenny Kwok Hei Yu, MBBS, PhD, FRCS; Cameron Brennan, MD; Whitney Stemple; MS; Nauman Abid, MD; Antoine Lampron, PhD; Viviane Tabar, MD

View More Download PDF

Oral Presentation

Presented at MDS

2024

Safety and Tolerability of Bemdaneprocel in People With Parkinson’s Disease: Results up to 24 Months From a Phase 1 Study

Harini Sarva, MD; Claire Henchcliffe, MD, DPhil; Andres Lozano, MD, PhD; Alfonso Fasano, MD, PhD; Suneil Kalia, MD, PhD, FAANS, FRCSC; Kenny Kwok Hei Yu, MBBS, PhD, FRCS; Cameron Brennan, MD; Whitney Stemple; MS; Nicole Floro, MS; Nauman Abid, MD; Antoine Lampron, PhD; Viviane Tabar, MD

View More Download PDF

Oral Presentation

Presented at ADPD

2024

Safety, Tolerability, and Clinical Assessment of Bemdaneprocel for Parkinson’s Disease: Results up to 18 Months From a Phase 1 Study

Claire Henchcliffe, MD, DPhil; Harini Sarva, MD; Andres Lozano, MD, PhD; Alfonso Fasano, MD, PhD; Suneil Kalia, MD, PhD, FAANS, FRCSC; Kenny Kwok Hei Yu, MBBS, PhD, FRCS; Cameron Brennan, MD; Whitney Stemple; MS; Nauman Abid, MD; Marcus Yountz, MD, FAAN; Ahmed Enayetallah, MD, PhD; Antoine Lampron, PhD; Viviane Tabar, MD

View More Download PDF

Oral Presentation

Presented at ADPD

2024

Imaging Outcomes of a Dopaminergic Neuronal Cell Therapy for Parkinson’s Disease: 18-Month Results

Yilong Ma, PhD; Claire Henchcliffe, MD, DPhil; Harini Sarva, MD; Andres Lozano, MD, PhD; Alfonso Fasano, MD, PhD; Suneil Kalia, MD, PhD, FAANS, FRCSC; Kenny Kwok Hei Yu, MBBS, PhD, FRCS; Cameron Brennan, MD; Nicki Jennings, PhD; Whitney Stemple; MS; Nauman Abid, MD; Marcus Yountz, MD, FAAN; Ahmed Enayetallah, MD, PhD; Antoine Lampron, PhD; Viviane Tabar, MD; David Eidelberg, MD

View More Download PDF

Poster

Presented at ADPD

2024

Non-motor Effects of Bemdaneprocel for Parkinson’s Disease: Results up to 18 Months From a Phase 1 Study

Claire Henchcliffe, MD, DPhil; Harini Sarva, MD; Andres Lozano, MD, PhD; Alfonso Fasano, MD, PhD; Suneil Kalia, MD, PhD, FAANS, FRCSC; Kenny Kwok Hei Yu, MBBS, PhD, FRCS; Cameron Brennan, MD; Michele York, PhD, ABPP-CN; Whitney Stemple; MS; Nauman Abid, MD; Marcus Yountz, MD, FAAN; Ahmed Enayetallah, MD, PhD; Antoine Lampron, PhD; Viviane Tabar, MD

View More Download PDF

Poster

Presented at MDS

2023

Dopaminergic Neuronal Cell Therapy for Parkinson’s Disease: Results From a Phase 1 Study of Bemdaneprocel

Claire Henchcliffe, MD, DPhil; Harini Sarva, MD; Andres Lozano, MD, PhD; Alfonso Fasano, MD, PhD; Suneil Kalia, MD, PhD, FAANS, FRCSC; Kenny Kwok Hei Yu, MBBS, PhD, FRCS; Cameron Brennan, MD; Whitney Stemple; MS; Nauman Abid, MD; Marcus Yountz, MD, FAAN; Ahmed Enayetallah, MD, PhD; Antoine Lampron, PhD; Viviane Tabar, MD

View More Download PDF